PRVA

PRIVIA HEALTH GROUP, INC. (PRVA) Date: 2026-06-20 Current Price: $23.67

Structural Readiness

State: Context-only Current Price: $23.67 Extension: — Breakout Level: — (Not yet established) ATR at Breakout: — ATR Current: 2.8% (Productive) Pivot Strength: —

(2) The Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None named at this date.

This is a tactical, setup-led name. There is no named macro or secular thesis attached to PRVA in the current evidence base for this specific date. The conviction must be derived entirely from the quality of the structural setup (the forming coil) and the underlying business fundamentals reported in the most recent earnings cycle. We do not invent a thesis; we judge the name on the strength of its operational execution and the technical structure of the price action.

(3) The Business

Company Overview: Privia Health Group, Inc. operates as a physician enablement platform, facilitating the transition of independent providers and medical groups into Value-Based Care (VBC) arrangements. The company generates revenue primarily through Fee-For-Service (FFS) patient care collections and by managing risk in VBC contracts.

Business Model & Industry:

• Industry: Healthcare Services / Physician Enablement.
• Revenue Model: The company collects reimbursements for medical services provided by its network of providers. As of Q1 2026, FFS-patient care revenue represented 64.8% of total revenue, with the remainder derived from VBC risk arrangements.
• Network Growth: The company has aggressively expanded its provider network and attributed lives. As of March 31, 2026, Privia ended the quarter with 5,535 providers, a 13.6% increase year-over-year.
• Attributed Lives: Total attributed lives reached 1.6 million, up 26.5% from the prior year. This growth was driven by both organic expansion and acquisitions, specifically the December 2025 acquisition of an ACO business from Evolent Health, Inc., which added over 120,000 attributed lives.
• Segment Performance:
• Commercial: Attributed lives increased >17% to 913,000.
• Medicare: CMS Medicare program lives surged 62%.
• Medicaid: Medicaid attribution increased 36%.
• Financial Performance (Q1 2026):
• Practice Collections: Increased 14.6% year-over-year to $914.8 million.
• Profitability: Adjusted EBITDA rose 36.3% to $36.7 million, with EBITDA margins expanding 290 basis points to 28.5%.
• Cash Conversion: Management expects to convert approximately 80% of EBITDA to free cash flow.

(4) The Archetype and Conviction

Archetype: Margin Inflector / Growth Leader Rationale: The business fits the "Margin Inflector" archetype due to the rapid expansion of EBITDA margins (up 290 bps to 28.5%) alongside significant top-line growth. The company is successfully scaling its VBC model, which historically commands higher margins than pure FFS. The acquisition of the Evolent Health ACO and the 62% growth in Medicare Advantage lives suggest a successful pivot toward higher-value, risk-bearing contracts.

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. The Q1 2026 earnings data (May 7, 2026) provides robust, specific metrics on provider growth, life attribution, and margin expansion.
• Structural Quality: Moderate. The setup is "Forming," meaning the structural quality is present but unconfirmed. The ATR of 2.8% is healthy, suggesting the stock is not in a state of extreme distress or manic speculation.
• Setup Readiness: Partial. The price is holding above the support zone, but the breakout has not fired.
• Rerating Potential: Moderate to High. If the breakout occurs, the combination of 20% EBITDA growth guidance and 80% FCF conversion could support a multiple expansion, provided the market recognizes the margin inflection.

(5) Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Continued Margin Expansion: Future quarters showing EBITDA margins exceeding 28.5% would validate the inflection thesis.
• Guidance Raise: Management raising the midpoint of the 20% EBITDA growth guidance would signal stronger-than-expected momentum.

What Would Invalidate the Case:

• Growth Deceleration: A significant slowdown in attributed lives growth or provider additions compared to the 13-26% growth rates seen in Q1 2026.
• Margin Compression: A drop in EBITDA margins below 25% would suggest the VBC model is not scaling efficiently.

Gaps in Evidence:

• Long-Term Capital Allocation: While acquisitions are noted, specific details on future M&A strategy beyond the 2025 Evolent deal are not detailed in the provided evidence.
• Debt Structure: The evidence does not explicitly detail the company's leverage ratios or debt maturity schedule as of June 2026, which is a standard risk factor for growth healthcare companies.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 EBITDA margin expansion to 28.5% with 36.3% growth; 26.5% YoY increase in attributed lives to 1.6 million; 14.6% growth in practice collections to $914.8 million. Key risks: Setup remains in "forming" state with no confirmed breakout; tactical nature lacks a named secular thesis; potential for margin compression if VBC risk management fails. Expected path: Management expects 20% EBITDA growth and 80% FCF conversion; if the breakout fires, the stock may re-rate based on the margin inflection narrative. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed trend or invalidation.